| Literature DB >> 19302713 |
Luzius B Hiltebrand1, Oliver Kimberger, Michael Arnberger, Sebastian Brandt, Andrea Kurz, Gisli H Sigurdsson.
Abstract
INTRODUCTION: Perioperative hypovolemia arises frequently and contributes to intestinal hypoperfusion and subsequent postoperative complications. Goal-directed fluid therapy might reduce these complications. The aim of this study was to compare the effects of goal-directed administration of crystalloids and colloids on the distribution of systemic, hepatosplanchnic, and microcirculatory (small intestine) blood flow after major abdominal surgery in a clinically relevant pig model.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19302713 PMCID: PMC2689484 DOI: 10.1186/cc7761
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Figure 1Systemic hemodynamic parameters. (a) Changes in mixed venous oxygen saturation (SvO2) (mean ± SD) before (baseline) and during the different fluid treatment strategies. SvO2 was the target parameter for fluid administration. (b) Changes in mean arterial pressure (mean ± SD) before (baseline) and during the different fluid treatment strategies. (c) Changes in cardiac index (mean ± SD) before (baseline) and during the different fluid treatment strategies. The restricted Ringer lactate fluid therapy (R-RL) group received 3 mL/kg per hour of lactated Ringer solution throughout the entire experiment. The goal-directed Ringer lactate fluid therapy (GD-RL) group received 3 mL/kg per hour of lactated Ringer solution plus 250 mL of lactated Ringer solution if SvO2 was less than 60%. The goal-directed colloid fluid therapy (GD-C) group received 3 mL/kg per hour of lactated Ringer solution plus 250 mL of hydroxyethyl starch (130/0.4) if SvO2 was less than 60%. Significant differences (P < 0.05) for area under the curve: #R-RL versus GD-RL, †R-RL versus GD-C, $GD-RL versus GD-C. Significant differences (P < 0.05) for analysis of variance for repeated measurements (Tukey post hoc test): *R-RL versus GD-RL, ≠R-RL versus GD-C, §GD-RL versus GD-C. SD, standard deviation.
Systemic, regional, and local hemodynamic variables
| Heart ratea, b (beats per minute) | SVb (mL/beat) | SVRIa, b (mm Hg/kg per minute) | CVP (mm Hg) | HVP (mm Hg) | PCWPb (mm Hg) | CeliacusI (mL/kg per minute) | MBF JMa, b (percentage of baseline) | |
| Restricted Ringer lactate solution (R-RL) | ||||||||
| 0 minutes | 117 ± 2 | 28.1 ± 8.4 | 732 ± 84 | 2.8 ± 1 | 3.8 ± 1.4 | 3.1 ± 0.6 | 4.0 ± 0.9 | 100 ± 0 |
| 30 minutes | 117 ± 4 | 26.6 ± 6.7 | 744 ± 123 | 3.1 ± 0.8 | 4.5 ± 1 | 3.3 ± 0.7 | 4.1 ± 1.0 | 93 ± 20 |
| 180 minutes | 123 ± 15 | 23.7 ± 5.7 | 868 ± 161 | 3.3 ± 0.7 | 3.9 ± 1.4 | 3.2 ± 0.9 | 4.9 ± 1.2 | 74 ± 24 |
| 240 minutes | 128 ± 14 | 24.2 ± 5.2 | 835 ± 149 | 2.8 ± 1.1 | 3.9 ± 0.9 | 2.9 ± 0.7 | 5.1 ± 1.1 | 71 ± 18 |
| Goal-directed Ringer lactate solution (GD-RL) | ||||||||
| 0 minutes | 110 ± 11 | 25.4 ± 6.6 | 705 ± 140 | 3 ± 1.1 | 4.3 ± 1.4 | 3.3 ± 1.1 | 3.8 ± 1.4 | 100 ± 0 |
| 30 minutes | 101 ± 4 | 28.3 ± 7 | 652 ± 157 | 3.3 ± 1.1 | 4.6 ± 1.1 | 3.6 ± 1 | 3.9 ± 1.5 | 97 ± 22 |
| 180 minutes | 106 ± 15a | 30.8 ± 6.5 | 666 ± 147 | 3.8 ± 1.1 | 5.5 ± 0.9 | 3.9 ± 1.2 | 6.2 ± 1.7 | 54 ± 18 |
| 240 minutes | 103 ± 18a, c | 33.2 ± 6.7 | 646 ± 90a | 4 ± 0.9 | 5.6 ± 1 | 4.4 ± 1.2 | 5.8 ± 1.1 | 49 ± 11 |
| Goal-directed colloid solution (GD-C) | ||||||||
| 0 minutes | 113 ± 7 | 25.2 ± 9.8 | 682 ± 155 | 3 ± 0.7 | 4.1 ± 0.9 | 3.3 ± 0.5 | 4.3 ± 1.3 | 100 ± 0 |
| 30 minutes | 98 ± 9 | 38.7 ± 7.3d | 589 ± 76 | 4.3 ± 0.7d | 5.4 ± 1 | 4.6 ± 0.8 | 5.0 ± 1.5 | 122 ± 19 |
| 180 minutes | 106 ± 16d | 35.1 ± 11d | 622 ± 109d | 3.8 ± 1.1 | 5.1 ± 1 | 3.9 ± 1.1 | 5.4 ± 1.5 | 101 ± 19d, e |
| 240 minutes | 109 ± 20d | 33.9 ± 12 | 563 ± 53d | 4.2 ± 0.9d | 5.7 ± 0.9 | 3.7 ± 0.9 | 5.4 ± 1.5 | 94 ± 22d, e |
Data are presented as mean ± standard deviation. Microcirculatory blood flow was set at 100% at t = 0 minutes. t = 0 baseline values are from before the start of the respective fluid therapy. At t = 30 minutes, effects of one fluid bolus, 250 mL of lactated Ringer solution in the GD-LR group or hydroxyethyl starch in the GD-C group, are presented. At t = 240 minutes, effects after an additional 1,794 ± 211 mL of lactated Ringer solution in the GD-LR group and an additional 831 ± 267 mL of hydroxyethyl starch (130/0.4) in the GD-C group are presented. Significant differences (P < 0.05) for area under the curve: aR-RL versus GD-RL, bR-RL versus GD-C. Significant differences (P < 0.05) for analysis of variance for repeated measurements (Tukey post hoc test): cR-RL versus GD-RL, dR-RL versus GD-C, eGD-RL versus GD-C. The R-RL group received 3 mL/kg per hour of lactated Ringer solution throughout the entire experiment. The GD-RL group received 3 mL/kg per hour of lactated Ringer solution plus 250 mL of lactated Ringer solution if SvO2 was less than 60%. The GD-C group received 3 mL/kg per hour of lactated Ringer solution plus 250 mL of hydroxyethyl starch (130/0.4) if SvO2 was less than 60%. CeliacusI, truncus celiacus flow index; CVP, central venous pressure; HVP, hepatic venous pressure; MBF JM, microcirculatory blood flow in the muscularis of the jejunum; PCWP, pulmonary capillary wedge pressure; SV, stroke volume; SVRI, systemic vascular resistance index.
Figure 2Regional blood flow parameters. (a) Changes in superior mesenteric artery flow index (mean ± SD) before (baseline) and during the different fluid treatment strategies. (b) Changes in hepatic artery flow index (mean ± SD) before (baseline) and during the different fluid treatment strategies. (c) Changes in carotid artery flow index (mean ± SD) before (baseline) and during the different fluid treatment strategies. The restricted Ringer lactate fluid therapy (R-RL) group received 3 mL/kg per hour of lactated Ringer solution throughout the entire experiment. The goal-directed Ringer lactate fluid therapy (GD-RL) group received 3 mL/kg per hour of lactated Ringer solution plus 250 mL of lactated Ringer solution if mixed venous oxygen saturation (SvO2) was less than 60%. The goal-directed colloid fluid therapy (GD-C) group received 3 mL/kg per hour of lactated Ringer solution plus 250 mL of hydroxyethyl starch (130/0.4) if SvO2 was less than 60%. Significant differences (P < 0.05) for area under the curve: #R-RL versus GD-RL, †R-RL versus GD-C, $GD-RL versus GD-C. Significant differences (P < 0.05) for analysis of variance for repeated measurements (Tukey post hoc test): *R-RL versus GD-RL, ≠R-RL versus GD-C, §GD-RL versus GD-C. SD, standard deviation.
Figure 3Intestinal perfusion and oxygenation parameters. (a) Relative changes in microcirculatory blood flow in the jejunum mucosa (mean ± SD) before (baseline) and during the different fluid treatment strategies. Blood flow was set at 100% at baseline. (b) Changes in jejunum wall tissue oxygen tension (mean ± SD) before (baseline) and during the different fluid treatment strategies. (c) Changes in mucosal carbon dioxide tension in the jejunum (mean ± SD) before (baseline) and during the different fluid treatment strategies. The restricted Ringer lactate fluid therapy (R-RL) group received 3 mL/kg per hour of lactated Ringer solution throughout the entire experiment. The goal-directed Ringer lactate fluid therapy (GD-RL) group received 3 mL/kg per hour of lactated Ringer solution plus 250 mL of lactated Ringer solution if mixed venous oxygen saturation (SvO2) was less than 60%. The goal-directed colloid fluid therapy (GD-C) group received 3 mL/kg per hour of lactated Ringer solution plus 250 mL of hydroxyethyl starch (130/0.4) if SvO2 was less than 60%. Significant differences (P < 0.05) for area under the curve: #R-RL versus GD-RL, †R-RL versus GD-C, $GD-RL versus GD-C. Significant differences (P < 0.05) for analysis of variance for repeated measurements (Tukey post hoc test): *R-RL versus GD-RL, ≠R-RL versus GD-C, §GD-RL versus GD-C. SD, standard deviation.
Figure 4Relative changes in intestinal microcirculation and tissue oxygen tension (ptiO2). Black squares indicate relative changes in microcirculatory blood flow (MBF) in the goal-directed colloid fluid therapy (GD-C) group. Open squares indicate relative changes in ptiO2 in the GD-C group. Black triangles indicate relative changes in MBF in the goal-directed Ringer lactate fluid therapy (GD-RL) group. Open triangles indicate relative changes in ptiO2 in the GD-RL group. Black circles indicate relative changes in MBF in the restricted Ringer lactate fluid therapy (R-RL) group. Open circles indicate relative changes in ptiO2 in the R-RL group. The R-RL group received 3 mL/kg per hour of lactated Ringer solution throughout the entire experiment. The GD-RL group received 3 mL/kg per hour of lactated Ringer solution plus 250 mL of lactated Ringer solution if mixed venous oxygen saturation (SvO2) was less than 60%. The GD-C group received 3 mL/kg per hour of lactated Ringer solution plus 250 mL of hydroxyethyl starch (130/0.4) if SvO2 was less than 60%. Baseline was set at 100% for all parameters. Significant differences (P < 0.05) for area under the curve: †R-RL versus GD-C, $GD-RL versus GD-C. Significant differences (P < 0.05) for analysis of variance for repeated measurements (Tukey post hoc test): ≠R-RL versus GD-C, §GD-RL versus GD-C.
Oxygen delivery, extraction, and other variables
| sDO2Ia, b (mL/kg per minute) | sERa-c (percentage) | mDO2Ib (mm Hg/kg per minute) | Mesent lac (mmol/L) | Arterial Hbb (g/L) | Arterial pH | Arterial pO2 (mm Hg) | Arterial pCO2 (mm Hg) | Arterial BE (mmol/L) | |
| Restricted Ringer lactate solution (R-RL) | |||||||||
| 0 minutes | 109 ± 11 | 49 ± 5 | 25 ± 2 | 1.5 ± 0.4 | 101 ± 7 | 7.51 ± 0.02 | 138 ± 9 | 36 ± 2 | 5.4 ± 0.9 |
| 60 minutes | 103 ± 11 | 48 ± 6 | 26 ± 2 | 1.4 ± 0.6 | 102 ± 6 | 7.51 ± 0.02 | 135 ± 10 | 36 ± 3 | 5.3 ± 1.2 |
| 180 minutes | 97 ± 12 | 50 ± 6 | 21 ± 2 | 1.2 ± 0.3 | 105 ± 9 | 7.5 ± 0.02 | 134 ± 15 | 36 ± 2 | 4.5 ± 1.7 |
| 240 minutes | 97 ± 12 | 50 ± 4 | 20 ± 1 | 1.3 ± 0.2 | 104 ± 6 | 7.49 ± 0.04 | 135 ± 12 | 37 ± 2 | 4.3 ± 2.0 |
| Goal-directed Ringer lactate solution (GD-RL) | |||||||||
| 0 minutes | 109 ± 17 | 51 ± 4 | 26 ± 6 | 1.4 ± 0.2 | 100 ± 10 | 7.52 ± 0.05 | 132 ± 11 | 37 ± 3 | 6.3 ± 1.9 |
| 60 minutes | 116 ± 19 | 50 ± 4 | 30 ± 8 | 1.2 ± 0.2 | 99 ± 10 | 7.52 ± 0.04 | 132 ± 10 | 36 ± 2 | 6.4 ± 2.0 |
| 180 minutes | 134 ± 26 | 44 ± 4 | 27 ± 6 | 1.2 ± 0.3 | 96 ± 6 | 7.49 ± 0.037 | 127 ± 10 | 38 ± 2 | 5.6 ± 2.0 |
| 240 minutes | 130 ± 18 | 42 ± 7 | 26 ± 7 | 1.2 ± 0.3 | 90 ± 8 | 49 ± 0.03 | 126 ± 9 | 38 ± 3 | 5.1 ± 2.1 |
| Goal-directed colloid solution (GD-C) | |||||||||
| 0 minutes | 116 ± 18 | 50 ± 6 | 26 ± 6 | 1.4 ± 0.4 | 97 ± 12 | 7.52 ± 0.03 | 135 ± 12 | 37 ± 3 | 5.8 ± 1.2 |
| 60 minutes | 141 ± 22c | 38 ± 5b, c | 35 ± 8 | 0.9 ± 0.2 | 86 ± 10 | 7.5 ± 0.02 | 132 ± 17 | 38 ± 3 | 5.7 ± 1.4 |
| 180 minutes | 151 ± 33d | 38 ± 4d, e | 29 ± 6d | 0.8 ± 0.3 | 89 ± 11d | 7.49 ± 0.02 | 131 ± 14 | 38 ± 1 | 5.0 ± 1.3 |
| 240 minutes | 158 ± 38d | 37 ± 5d | 27 ± 5d | 0.8 ± 0.3 | 87 ± 12d | 7.49 ± 0.02 | 128 ± 16 | 37 ± 1 | 4.6 ± 1.0 |
Data are presented as mean ± standard deviation. t = 0 baseline values are from before the start of the respective fluid therapy. The measurements were performed hourly for 4 hours. Significant differences (P < 0.05) for area under the curve: aR-RL versus GD-RL, bR-RL versus GD-C, cGD-RL versus GD-C. Significant differences (P < 0.05) for analysis of variance for repeated measurements (Tukey post hoc test): dR-RL versus GD-C, eGD-RL versus GD-C. The R-RL group received 3 mL/kg per hour of lactated Ringer solution throughout the entire experiment. The GD-RL group received 3 mL/kg per hour of lactated Ringer solution plus 250 mL of lactated Ringer solution if SvO2 was less than 60%. The GD-C group received 3 mL/kg per hour of lactated Ringer solution plus 250 mL of hydroxyethyl starch (130/0.4) if SvO2 was less than 60%. BE, standard base excess; Hb, hemoglobin concentration; mDO2I, mesenteric oxygen delivery; mesent lac, mesenteric venous lactate; pCO2, carbon dioxide partial pressure; pO2, oxygen partial pressure; sDO2, systemic oxygen delivery index; sER, systemic oxygen extraction ratio.
Figure 5Splanchnic oxygenation parameters. (a) Changes in hepatic vein oxygen saturation (mean ± SD) before (baseline) and during the different fluid treatment strategies. (b) Changes in mesenteric vein glucose (mean ± SD) before (baseline) and during the different fluid treatment strategies. (c) Changes in mesenteric oxygen extraction ratio (mean ± SD) before (baseline) and during the different fluid treatment strategies. (d) Changes in mesenteric vein lactate (mean ± SD) before (baseline) and during the different fluid treatment strategies. The restricted Ringer lactate fluid therapy (R-RL) group received 3 mL/kg per hour of lactated Ringer solution throughout the entire experiment. The goal-directed Ringer lactate fluid therapy (GD-RL) group received 3 mL/kg per hour of lactated Ringer solution plus 250 mL of lactated Ringer solution if mixed venous oxygen saturation (SvO2) was less than 60%. The goal-directed colloid fluid therapy (GD-C) group received 3 mL/kg per hour of lactated Ringer solution plus 250 mL of hydroxyethyl starch (130/0.4) if SvO2 was less than 60%. Significant differences (P < 0.05) for area under the curve: #R-RL versus GD-RL, †R-RL versus GD-C, $GD-RL versus GD-C. Significant differences (P < 0.05) for analysis of variance for repeated measurements (Tukey post hoc test): *R-RL versus GD-RL, ≠R-RL versus GD-C, §GD-RL versus GD-C. SD, standard deviation.